Johnson & Johnson (JNJ) Cash from Investing Activities (QoQ) (2009 - 2026)
Johnson & Johnson (JNJ) Cash from Investing Activities (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -6.73% |
| Mar 29, 2026 | 76.81% |
| Dec 28, 2025 | -727.49% |
| Sep 28, 2025 | 97.03% |
| Jun 29, 2025 | -6,049.49% |
| Mar 30, 2025 | 77.50% |
| Dec 29, 2024 | 57.80% |
| Sep 29, 2024 | 77.15% |
| Jun 30, 2024 | -2,849.78% |
| Mar 31, 2024 | 61.40% |
| Dec 31, 2023 | -147.30% |
| Oct 1, 2023 | 167.29% |
| Jul 2, 2023 | -213.91% |
| Apr 2, 2023 | 136.64% |
| Oct 3, 2021 | -548.93% |
| Jul 4, 2021 | -126.49% |
| Apr 4, 2021 | 97.66% |
| Jan 3, 2021 | -64.00% |
| Sep 27, 2020 | 35.93% |
| Jun 28, 2020 | -1,194.66% |